A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Status:
Completed
Trial end date:
2015-11-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of
your prostate cancer. The investigators will also watch you carefully for any side effects
that PX-866 might cause.